Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system
This comprehensive analysis of FAERS data enhances our understanding of the safety. These findings hold implications for ongoing clinical surveillance efforts and provide a foundational basis for subsequent investigations into the safety profiles of these agents.
Authors
- Haolin Teng
- Junsheng Yu (ORCID: https://orcid.org/0000-0002-7484-8114)
- Shengnan Zhang (ORCID: https://orcid.org/0000-0003-1051-7196)
- Faping Li (ORCID: https://orcid.org/0000-0003-3016-5159)
Institutions
- Jilin University (CN)
- First Hospital of Jilin University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.3389/fphar.2025.1518258
- Citations
- 2
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Natural Science Foundation of Jilin Province
- People's Government of Jilin Province